Results 21 to 30 of about 2,156,166 (288)

ON THE NOTION OF SYNERGY OF MONOCLONAL ANTIBODIES AS DRUGS [PDF]

Biotechnologia Acta, 2013
History of developing synergy between monoclonal antibodies, anti-tumor activity of monoclonal antibodies against tyrosine-kinases receptors EGFR/ErbB-1 and HER2/ErbB-2 as well as growth factor VEGF in various combinations are considered in the article ...
Michael Sela
doaj   +1 more source

Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy

Journal of Biomedical Science, 2022
Background Calls for the coronavirus to be treated as an endemic illness, such as the flu, are increasing. After achieving high coverage of COVID-19 vaccination, therapeutic drugs have become important for future SARS-CoV-2 variant outbreaks.
Chen-Yi Chiang, Mei-Yu Chen, Chia-Wei Hsu, Chia-Yeh Liu, Yu-Wen Tsai, Hung-Chun Liao, Jia-Ying Yan, Zih-Shiuan Chuang, Hsin-I. Wang, Chien-Hsiung Pan, Chia-Yi Yu, Guann-Yi Yu, Ching-Len Liao, Shih-Jen Liu, Hsin-Wei Chen   +14 more
doaj   +1 more source

Pharmacokinetics of Monoclonal Antibodies

CPT: Pharmacometrics & Systems Pharmacology, 2017
Monoclonal antibodies (mAbs) have developed in the last two decades into the backbone of pharmacotherapeutic interventions in a variety of indications, with currently more than 40 mAbs approved by the US Food and Drug Administration, and several dozens ...
J. Ryman, B. Meibohm
semanticscholar   +1 more source

The Use of Biotechnological Drugs in Pediatrics on the Example of Monoclonal Antibodies: Clinical Pharmacology View

Педиатрическая фармакология, 2021
The article reviews monoclonal antibodies, its structure, classifications, pharmacodynamics, pharmacokinetics, and adverse effects. There are examples for each section.
Alexey S. Kolbin, Liudmila I. Yemelyanova   +1 more
doaj   +1 more source

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

The Journal of Headache and Pain, 2019
Background and aimMonoclonal antibodies acting on the calcitonin gene-related peptide or on its receptor are new drugs to prevent migraine. Four monoclonal antibodies have been developed: one targeting the calcitonin gene-related peptide receptor ...
S. Sacco, L. Bendtsen, M. Ashina, U. Reuter, G. Terwindt, D. Mitsikostas, P. Martelletti   +6 more
semanticscholar   +1 more source

Washing with alkaline solutions in protein A purification improves physicochemical properties of monoclonal antibodies

Scientific Reports, 2021
Protein A affinity chromatography has been widely used for both laboratory scale purification and commercial manufacturing of monoclonal antibodies and Fc-fusion proteins. Protein A purification is specific and efficient.
Yuichi Imura, Toshiaki Tagawa, Yuya Miyamoto, Satoshi Nonoyama, Hiroshi Sumichika, Yasuhiro Fujino, Masaya Yamanouchi, Hideo Miki   +7 more
doaj   +1 more source

Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma

Leukemia Research Reports, 2022
The improvement in outcomes seen with the introduction of rituximab, a CD20 monoclonal antibody in combination with chemotherapy or as a single agent in the treatment of indolent non-Hodgkin lymphomas has paved the way for development of various forms of
Suheil Albert Atallah-Yunes, Michael J. Robertson   +1 more
doaj   +1 more source

The pharmacology and therapeutic applications of monoclonal antibodies

Pharmacology Research & Perspectives, 2019
Monoclonal antibodies (mAbs) have emerged as a major class of therapeutic agents on the market. To date, approximately 80 mAbs have been granted marketing approval.
María Sofía Castelli, P. Mcgonigle, P. Hornby   +2 more
semanticscholar   +1 more source

Monoclonal Antibodies

Dermatologic Clinics, 2015
Use of monoclonal antibodies (mAbs) has revolutionized cancer therapy. Approaches targeting specific cellular targets on the malignant cells and in tumor microenvironment have been proved to be successful in hematologic malignancies, including cutaneous lymphomas.
openaire   +3 more sources

Characterization of protective and non-protective surface membrane carbohydrate epitopes of Schistosoma mansoni

Memorias do Instituto Oswaldo Cruz, 1987
We have produced a number of monoclonal antibodies, protective and non-protective, which recognize a complex of schistosomula antigens, including the 38 kDa antigen. Eight different protective and non-protective monoclonal antibodies, varying in isotypes,
Albert I. Ko, Donald A. Harn
doaj   +1 more source